An investigation for investors in Alkermes Plc (NASDAQ: ALKS) shares over potential securities laws violations by Alkermes Plc was announced.
San Diego, CA -- (SBWIRE) -- 11/29/2018 -- An investigation was announced over potential securities laws violations by Alkermes Plc and certain of its directors and officers in connection with certain financial statements.
Investors who purchased shares of Alkermes Plc (NASDAQ: ALKS), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Alkermes Plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Ireland based Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
Alkermes Plc reported that its annual Total Revenue rose from $745.69 million in 2016 to $903.37 million in 2017 and that its Net Loss declined from $208.44 million in 2016 to $157.94 million in 2017.
On October 30, 2018, the U.S. Food and Drug Administration ("FDA") released a briefing document on Alkermes' New Drug Application for ALKS 5461 ahead of a scheduled FDA advisory committee meeting for the drug. The FDA briefing document revealed that Alkermes "used an abridged 6-item version of the MADRS-10 for the primary endpoint of one of the principal studies (Study 207)" rather than the "10-item diagnostic questionnaire (MADRS-10) used to measure the severity of depressive episodes in patients with mood disorders," despite the FDA's "advice explicitly against this plan." Moreover, the FDA briefing document revealed that the FDA "disagreed with [Alkermes'] planned strategy to average the MADRS results over several weeks, and recommended use of the MADRS-10EOT, as used in other antidepressant studies and as previously agreed."
Shares of Alkermes Plc (NASDAQ: ALKS) declined from $71.22 per share in February 2018 to as low $32.77 per share on November 14, 2018.
Those who purchased shares of Alkermes Plc (NASDAQ: ALKS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels